Primary sclerosing cholangitis differential diagnosis: Difference between revisions
Akshun Kalia (talk | contribs) No edit summary |
Akshun Kalia (talk | contribs) No edit summary |
||
Line 155: | Line 155: | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | {| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Disease | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Disease | ||
| colspan=" | | colspan="10" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Clinical manifestations''' | ||
! colspan="2" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Diagnosis | ! colspan="2" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Diagnosis | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Comments | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Comments | ||
|- | |- | ||
| colspan=" | | colspan="7" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Symptoms''' | ||
! colspan=" | ! colspan="3" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" | Signs | ||
|- | |- | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Abdominal Pain | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Abdominal Pain | ||
Line 167: | Line 167: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ||
Line 174: | Line 173: | ||
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" | Guarding | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" | Guarding | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ||
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" | Lab Findings | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" | Lab Findings | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ||
Line 184: | Line 182: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
Line 190: | Line 187: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Increased liver enzymes | * Increased liver enzymes | ||
Line 213: | Line 209: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
Line 219: | Line 214: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Abnormal [[LFT]] | *Abnormal [[LFT]] | ||
Line 234: | Line 228: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
Line 240: | Line 233: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Abnormal [[LFT]] | * Abnormal [[LFT]] | ||
Line 254: | Line 246: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
Line 260: | Line 251: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Hyperbilirubinemia]] | * [[Hyperbilirubinemia]] | ||
Line 276: | Line 266: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ||
Line 283: | Line 272: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Guarding | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Guarding | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ||
Line 294: | Line 282: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
Line 300: | Line 287: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Increased [[amylase]] / [[lipase]] | * Increased [[amylase]] / [[lipase]] | ||
Line 315: | Line 301: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 321: | Line 306: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Increased [[amylase]] / [[lipase]] | * Increased [[amylase]] / [[lipase]] | ||
Line 339: | Line 323: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 345: | Line 328: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* ↑ [[Alkaline phosphatase]] | * ↑ [[Alkaline phosphatase]] | ||
Line 366: | Line 348: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |− | ||
Line 372: | Line 353: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Increased AMA level, abnormal [[LFTs]] | * Increased AMA level, abnormal [[LFTs]] | ||
Line 391: | Line 371: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Leukocytosis]] | * [[Leukocytosis]] | ||
Line 411: | Line 389: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* ↑ [[bilirubin]] and [[alkaline phosphatase]] | * ↑ [[bilirubin]] and [[alkaline phosphatase]] | ||
Line 425: | Line 401: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ||
Line 432: | Line 407: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Guarding | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Guarding | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ||
Line 443: | Line 417: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 449: | Line 422: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Anti-neutrophil cytoplasmic antibody]] ([[P-ANCA]]) in [[Ulcerative colitis]] | * [[Anti-neutrophil cytoplasmic antibody]] ([[P-ANCA]]) in [[Ulcerative colitis]] | ||
Line 466: | Line 438: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 472: | Line 443: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Thrombocytopenia]] | * [[Thrombocytopenia]] | ||
Line 498: | Line 468: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in Hep A and E | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in Hep A and E | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 504: | Line 473: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in acute | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in acute | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Abnormal LFTs | * Abnormal LFTs | ||
Line 520: | Line 488: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Nausea or vomiting | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Jaundice | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ||
Line 527: | Line 494: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Guarding | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Guarding | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Rebound Tenderness | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Imaging | ||
Line 538: | Line 504: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 544: | Line 509: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ± | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* CBC | * CBC | ||
Line 560: | Line 524: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 566: | Line 529: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* High levels of [[Alpha-fetoprotein|AFP]] in serum | * High levels of [[Alpha-fetoprotein|AFP]] in serum | ||
Line 590: | Line 550: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
Line 596: | Line 555: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* [[Hypoalbuminemia]] | * [[Hypoalbuminemia]] | ||
Line 616: | Line 574: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in cirrhotic patients | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | Positive in cirrhotic patients | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | − | ||
Line 622: | Line 579: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
* Ascitic fluid [[PMN]]>250 cells/mm<small>³</small> | * Ascitic fluid [[PMN]]>250 cells/mm<small>³</small> |
Revision as of 19:08, 8 February 2018
Primary sclerosing cholangitis Microchapters |
Differentiating Primary sclerosing cholangitis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Primary sclerosing cholangitis differential diagnosis On the Web |
American Roentgen Ray Society Images of Primary sclerosing cholangitis differential diagnosis |
FDA on Primary sclerosing cholangitis differential diagnosis |
CDC on Primary sclerosing cholangitis differential diagnosis |
Primary sclerosing cholangitis differential diagnosis in the news |
Blogs on Primary sclerosing cholangitis differential diagnosis |
Directions to Hospitals Treating Primary sclerosing cholangitis |
Risk calculators and risk factors for Primary sclerosing cholangitis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2]
Overview
Primary sclerosing cholangitis must be differentiated from causes of secondary sclerosing cholangitis.
Differentiating Primary sclerosing cholangitis from other Diseases
Primary sclerosing cholangitis must be differentiated from causes of secondary sclerosing cholangitis. These include:[1][2]
- Abdominal trauma
- AIDS-related cholangiopathy
- Amyloidosis
- Chronic bacterial cholangitis
- GVHD
- Hepatic inflammatory pseudo tumor
- Histiocytosis X
- Iatrogenic biliary strictures, due to surgery or ERCP
- IgG4-associated cholangitis
- Infectious or ischemic cholangiopathy
- Cholangiocarcinoma
- Choledocholithiasis
- Diffuse intra-hepatic metastases
- Eosinophilic cholangitis
- Intra-arterial chemotherapy
- Mast cell cholangiopathy
- Portal hypertensive biliopathy
- Recurrent pancreatitis
- Recurrent pyogenic cholangitis
- Sarcoidosis
Primary sclerosing cholangitis must be differentiated from other causes of jaundice:
|
Abbreviations: RUQ= Right upper quadrant of the abdomen, LUQ= Left upper quadrant, LLQ= Left lower quadrant, RLQ= Right lower quadrant, LFT= Liver function test, SIRS= Systemic inflammatory response syndrome, ERCP= Endoscopic retrograde cholangiopancreatography, IV= Intravenous, N= Normal, AMA= Anti mitochondrial antibodies, LDH= Lactate dehydrogenase, GI= Gastrointestinal, CXR= Chest X ray, IgA= Immunoglobulin A, IgG= Immunoglobulin G, IgM= Immunoglobulin M, CT= Computed tomography, PMN= Polymorphonuclear cells, ESR= Erythrocyte sedimentation rate, CRP= C-reactive protein, TS= Transferrin saturation, SF= Serum Ferritin, SMA= Superior mesenteric artery, SMV= Superior mesenteric vein, ECG= Electrocardiogram
Primary sclerosing cholangitis must be differentiated from other abdominal pain causes:
|
References
- ↑ Lazaridis KN, LaRusso NF (2016). "Primary Sclerosing Cholangitis". N. Engl. J. Med. 375 (12): 1161–70. doi:10.1056/NEJMra1506330. PMID 27653566.
- ↑ Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010). "Diagnosis and management of primary sclerosing cholangitis". Hepatology. 51 (2): 660–78. doi:10.1002/hep.23294. PMID 20101749.